Skip to main content
John Kirkwood, MD, Oncology, Pittsburgh, PA, UPMC Presbyterian Shadyside

JohnMunnKirkwoodMD

Oncology • Pittsburgh, PA

Melanoma

Usher Professor of Medicine, Dermatology & Translational Science; Director, Melanoma and Skin Cancer Program University of Pittsburgh School of Medicine

Join to view full profile

Dr. Kirkwood is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kirkwood's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1977 - 1979
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 1973 - 1976
  • Yale School of Medicine
    Yale School of MedicineClass of 1973

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1986 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors for Cancer Castle Connolly, 2005-2019
  • Pittsburgh Magazine Best Doctors Castle Connolly, 2005-2019
  • Distinguished Service Professor of Medicine University of Pittsburgh, 2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Prognostic Gene Expression Profiling in Cutaneous Melanoma  
    Douglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology
  • Psychosocial Impact of Skin Biopsies in the Setting of Melanoma Screening – A Cross‐Sectional Survey  
    M A Weinstock, L K Ferris, N H Matthews, J M Kirkwood, F Solano, M Saul, A C Geller, The British Journal of Dermatology

Lectures

  • Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma 
    Imedex, Baltimore, Maryland - 9/13/2013

Authored Content

  • Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020

Press Mentions

  • Science News | Patients with High-Risk Local Melanomas Benefit from Immunotherapy Drug: Study
    Science News | Patients with High-Risk Local Melanomas Benefit from Immunotherapy Drug: StudySeptember 20th, 2021
  • Immunotherapy Drug Benefits Patients with High-Risk Local Melanomas
    Immunotherapy Drug Benefits Patients with High-Risk Local MelanomasSeptember 18th, 2021
  • ASCO21 Preview - Equity: Every Patient. Every Day. Everywhere
    ASCO21 Preview - Equity: Every Patient. Every Day. EverywhereMay 27th, 2021
  • Join now to see all

Grant Support

  • Spore In Skin CancerNational Cancer Institute2008–2011
  • Immunologic &Genetic Determinants Of Outcome &Response To Ifn-A2b TherapyNational Cancer Institute2008–2011
  • Career Development ProgramNational Cancer Institute2008–2011
  • AdministrativeNational Cancer Institute2008–2011
  • Eastern Cooperative Oncology Group (Main Institution)National Cancer Institute2004–2011
  • Eastern Cooporative Oncology Group (Main Institution)National Cancer Institute2007–2009
  • Eastern Cooperative Oncology Gruop (Main Institution)National Cancer Institute2005–2006
  • Randomized Placebo Control Ph3 Trial Yeast Derived GM-CSF VS Peptide VaccinatinNational Center For Research Resources2005
  • RAND Ph2 Eval Immun Agst Tumor Cells PTS W/Metast Melanoma Dendritic CellsNational Center For Research Resources2005
  • Ph1/Ii Vaccination W/Melan-A/Mart-1 Multi-Epitope Cont Melan-A/Mart PeptidesNational Center For Research Resources2005
  • Eval Local GM-CSF Adjuvant Number Vaccine Sites Immuniz W/MsmpNational Center For Research Resources2005
  • Ph3 Trial Yeast Derived GM-CSF Vs. Peptide VaccinationNational Center For Research Resources2004
  • Ph2 HLA-A2 Multiepitope Peptide Vaccine &TyrosinaseNational Center For Research Resources2004
  • Ph1/Ii Vaccination With Melan-A/Mart-1 Multi-EpitopeNational Center For Research Resources2004
  • Dendritic Cell Immunization For Metastatic MelanomaNational Center For Research Resources2004
  • Peptide Vaccines With/Without Gmcsf In Stage IV MelanomaNational Cancer Institute2000–2004
  • Eastern Cooperative Oncology GroupNational Cancer Institute1989–2003
  • High Dose IFN Alfa 2B P450 Enzyme System PTS W/ High Risk MelanomaNational Center For Research Resources1999–2002
  • Phase II Trial Of GM2 Khl/Qs21 Vaccine With Interferon Alpha 2B In MelanomaNational Center For Research Resources1998–2002
  • Phase III Study Of Adjuvant Ganglioside Vaccination VS Interferon TherapyNational Center For Research Resources1997–2002
  • Biologic Therapy Research Career Development ProgramNational Cancer Institute2000
  • Phase II Study Of Rhil 12 IV Injections In Advanced Malignant Melanoma PatientsNational Center For Research Resources1998–2000
  • Multicenter Pilot Study Of Tucaresol In Metastatic MelanomaNational Center For Research Resources1997–2000
  • High Dose IFN Alpha In P450 Enzyme System In MelanomaNational Center For Research Resources1999
  • Phase I Study Of SCH 52365 In Combination With Interferon A-2bNational Center For Research Resources1996–1999
  • Mechanism Of Melanoma Vaccine Gm2-Klh/Qs21National Cancer Institute1997–1998
  • Multicenter Dose-Range Finding Pilot Study Of Tucaresol In Metastatic MelanomaNational Center For Research Resources1996
  • OncologyNational Cancer Institute1994
  • IFN Alfa-2b And The Immunobiology Of MelanomaNational Cancer Institute1994
  • Role Of IFN Alfa-2b In The Immunobiology Of MelanomaNational Cancer Institute1992–1993
  • Research And Training In Medical OncologyNational Cancer Institute1991–1993

Professional Memberships

Hospital Affiliations

Dr. John Kirkwood, Dr. John Kirkwood, MD, Dr. J Kirkwood, Dr. John Munn Kirkwood